Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
Top Cited Papers
Open Access
- 1 February 2000
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 82 (4), 812-817
- https://doi.org/10.1054/bjoc.1999.1004
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Thalidomide in Crohn's diseaseThe Lancet, 1997
- Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the vicenza studiesEuropean Journal Of Cancer, 1996
- Role of soluble mediators in angiogenesisEuropean Journal Of Cancer, 1996
- Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancerEuropean Journal Of Cancer, 1996
- Angiogenesis Research Enjoys Growth Spurt in the 1990sJNCI Journal of the National Cancer Institute, 1996
- Guideline for the clinical use and dispensing of thalidomidePublished by Oxford University Press (OUP) ,1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Rapid Cytokine Release in Cancer Patients Treated with Interleukin-2Journal of Immunotherapy, 1992
- Interleukin-6 and renal cell cancer: Production, regulation, and growth effectsCancer Immunology, Immunotherapy, 1992
- Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growthNature, 1990